David P Kelsen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/545287/publications.pdf

Version: 2024-02-01

82 papers	6,355 citations	87888 38 h-index	71685 76 g-index
85 all docs	85 docs citations	85 times ranked	7295 citing authors

#	Article	IF	Citations
1	Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers. Cell, 2020, 182, 1044-1061.e18.	28.9	691
2	Long-Term Results of RTOG Trial 8911 (USA Intergroup 113): A Random Assignment Trial Comparison of Chemotherapy Followed by Surgery Compared With Surgery Alone for Esophageal Cancer. Journal of Clinical Oncology, 2007, 25, 3719-3725.	1.6	489
3	Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations. Clinical Cancer Research, 2018, 24, 1326-1336.	7.0	281
4	Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation. Journal of Clinical Oncology, 2020, 38, 1378-1388.	1.6	265
5	Phase II Trial of Weekly Irinotecan Plus Cisplatin in Advanced Esophageal Cancer. Journal of Clinical Oncology, 1999, 17, 3270-3275.	1.6	246
6	First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. Lancet Oncology, The, 2020, 21, 821-831.	10.7	243
7	An Emerging Entity: Pancreatic Adenocarcinoma Associated with a Known BRCA Mutation: Clinical Descriptors, Treatment Implications, and Future Directions. Oncologist, 2011, 16, 1397-1402.	3.7	227
8	Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone, and diphenhydramine. Results of consecutive trials in 255 patients. Cancer, 1985, 55, 527-534.	4.1	217
9	Cancer of the esophagus and esophagogastric junctionâ€"Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. Ca-A Cancer Journal for Clinicians, 2017, 67, 304-317.	329.8	212
10	Phase II Study of the Cyclin-Dependent Kinase Inhibitor Flavopiridol Administered to Patients With Advanced Gastric Carcinoma. Journal of Clinical Oncology, 2001, 19, 1985-1992.	1.6	198
11	Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms. Journal of the National Cancer Institute, 2018, 110, 1067-1074.	6.3	170
12	Identification of germline genetic mutations in patients with pancreatic cancer. Cancer, 2015, 121, 4382-4388.	4.1	167
13	Genomic Alterations Observed in Colitis-Associated Cancers Are Distinct From Those Found in Sporadic Colorectal Cancers and Vary by Type of Inflammatory Bowel Disease. Gastroenterology, 2016, 151, 278-287.e6.	1.3	147
14	Interferon alpha-2a and 5-fluorouracil for advanced colorectal carcinoma assessment of activity and toxicity. Cancer, 1990, 66, 2470-2475.	4.1	136
15	Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection. Clinical Cancer Research, 2020, 26, 3239-3247.	7.0	135
16	Preoperative 5-fluorouracil, low-dose leucovorin, and concurrent radiation therapy for rectal cancer. Cancer, 1994, 73, 273-280.	4.1	125
17	Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma. European Journal of Cancer, 2018, 89, 19-26.	2.8	125
18	The efficacy of preoperative 5-fluorouracil, high-dose leucovorin, and sequential radiation therapy for unresectable rectal cancer. Cancer, 1993, 71, 3486-3492.	4.1	104

#	Article	IF	Citations
19	Radiation-induced angiosarcoma. Cancer, 1987, 60, 777-779.	4.1	102
20	Targeted cytogenetic analysis of gastric tumors byin situhybridization with a set of chromosome-specific dna probes. Cancer, 1990, 66, 491-497.	4.1	94
21	Small cell carcinoma of the esophagus. The memorial hospital experience 1970 to 1987. Cancer, 1989, 64, 1531-1533.	4.1	91
22	Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wildâ€type BRCA pancreatic ductal adenocarcinoma. Cancer, 2018, 124, 1374-1382.	4.1	91
23	Adenocarcinoma of the esophagus and gastroesophageal junction. Prognostic factors and results of therapy. Cancer, 1985, 56, 2512-2518.	4.1	90
24	The mutational status of p53 protein in gastric and esophageal adenocarcinoma cell lines predicts sensitivity to chemotherapeutic agents. International Journal of Cancer, 1995, 64, 37-46.	5.1	86
25	A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma. Journal of Hepatology, 2014, 60, 319-324.	3.7	83
26	A Phase II study of irinotecan in patients with advanced hepatocellular carcinoma. Cancer, 2001, 91, 101-105.	4.1	80
27	In Vivo PET Assay of Tumor Glutamine Flux and Metabolism: In-Human Trial of ¹⁸F-(2S,4R)-4-Fluoroglutamine. Radiology, 2018, 287, 667-675.	7.3	80
28	A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma. Cancer, 1991, 68, 965-969.	4.1	79
29	Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer. Clinical Cancer Research, 2019, 25, 6160-6169.	7.0	73
30	Pharmacokinetics of gallium nitrate in man. Cancer, 1980, 46, 2009-2013.	4.1	72
31	A phase II trial of recombinant tumor necrosis factor in patients with advanced colorectal carcinoma. Cancer, 1990, 66, 659-663.	4.1	72
32	Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer. British Journal of Cancer, 2017, 116, 697-702.	6.4	70
33	A phase II trial of alpha-interferon and 5-fluorouracil in patients with advanced carcinoid and islet cell tumors. Cancer, 1994, 74, 958-961.	4.1	64
34	Selective inhibition of cyclooxygenase-2 enhances mitomycin-C-induced apoptosis. Cancer Chemotherapy and Pharmacology, 2000, 45, 389-396.	2.3	55
35	Heat Shock Factor 1-dependent extracellular matrix remodeling mediates the transition from chronic intestinal inflammation to colon cancer. Nature Communications, 2020, 11, 6245.	12.8	51
36	30 Gy may be an adequate dose in patients with anal cancer treated with excisional biopsy followed by combined-modality therapy. , 1999, 70, 71-77.		45

#	Article	IF	Citations
37	Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma. Cancer, 2020, 126, 3939-3949.	4.1	44
38	A phase I trial of immediate postoperative intraperitoneal floxuridine and leucovorin plus systemic 5-fluorouracil and levamisole after resection of high risk colon cancer. Cancer, 1994, 74, 2224-2233.	4.1	41
39	The newly proposed clinical and post-neoadjuvant treatment staging classifications for gastric adenocarcinoma for the American Joint Committee on Cancer (AJCC) staging. Gastric Cancer, 2018, 21, 1-9.	5.3	41
40	Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches. Expert Review of Gastroenterology and Hepatology, 2016, 10, 1-13.	3.0	39
41	Neoadjuvant chemotherapy and surgery of cancer of the esophagus. Journal of Surgical Oncology, 1990, 6, 268-273.	1.4	35
42	Early-Onset Pancreas Cancer: Clinical Descriptors, Genomics, and Outcomes. Journal of the National Cancer Institute, 2021, 113, 1194-1202.	6.3	35
43	Defining the invasive phenotype of proximal gastric cancer cells. Cancer, 1994, 73, 22-27.	4.1	32
44	Cell-free DNA (cfDNA) and Exosome Profiling from a Year-Long Human Spaceflight Reveals Circulating Biomarkers. IScience, 2020, 23, 101844.	4.1	31
45	Change in chemotherapy during concurrent radiation followed by surgery after a suboptimal positron emission tomography response to induction chemotherapy improves outcomes for locally advanced esophageal adenocarcinoma. Cancer, 2016, 122, 2083-2090.	4.1	30
46	9-aminocamptothecin by 72-hour continuous intravenous infusion is Inactive in the treatment of patients with 5-fluorouracil-refractory colorectal carcinoma. , 1997, 80, 1727-1732.		29
47	A Phase II Trial of Interferon Alpha-2a and Carboplatin in Patients with Advanced Malignant Mesothelioma. Cancer Investigation, 1999, 17, 195-200.	1.3	29
48	A phase II trial of interferon alpha-2A, 5-fluorouracil, and cisplatin in patients with advanced esophageal carcinoma. Cancer, 1995, 75, 2197-2202.	4.1	28
49	Cisplatin, vindesine and bleomycin (CVB) combination chemotherapy of advanced non-small cell lung cancer. Cancer, 1983, 51, 1050-1055.	4.1	26
50	Phase II trial of gemcitabine in patients with advanced gastric cancer. Cancer, 1994, 73, 5-7.	4.1	25
51	Pancreas cancer and BRCA: A critical subset of patients with improving therapeutic outcomes. Cancer, 2021, 127, 4393-4402.	4.1	24
52	Treatment, Outcomes, and Clinical Trial Participation in Elderly Patients With Metastatic Pancreas Adenocarcinoma. Clinical Colorectal Cancer, 2015, 14, 269-276.e1.	2.3	23
53	Characterization and Clinical Outcomes of DNA Mismatch Repairâ€“deficient Small Bowel Adenocarcinoma. Clinical Cancer Research, 2021, 27, 1429-1437.	7.0	23
54	Neoadjuvant chemotherapy and surgery of cancer of the esophagus. Journal of Surgical Oncology, 1986, 2, 170-176.	1.4	21

#	Article	IF	Citations
55	ADJUVANT TREATMENT OF COLORECTAL CANCER. Annual Review of Medicine, 1997, 48, 191-202.	12.2	21
56	Different hotspot p53 mutants exert distinct phenotypes and predict outcome of colorectal cancer patients. Nature Communications, 2022, 13, 2800.	12.8	21
57	Induction and characterization of pancreatic cancer in a transgenic pig model. PLoS ONE, 2020, 15, e0239391.	2.5	19
58	Efficacy of Postoperative 5-FU, High-Dose Leucovorin, and Sequential Radiation Therapy for Clinically Resectable Rectal Cancer. Cancer Investigation, 1995, 13, 1-7.	1.3	16
59	Positron-Emission Tomography Scanâ€"Directed Chemoradiation for Esophageal Squamous Cell Carcinoma: No Benefit for a Change in Chemotherapy in Positron-Emission Tomography Nonresponders. Journal of Thoracic Oncology, 2019, 14, 540-546.	1.1	15
60	Extracellular vesicle and particle isolation from human and murine cell lines, tissues, and bodily fluids. STAR Protocols, 2021, 2, 100225.	1.2	15
61	Prevalence of Germline Alterations on Targeted Tumor-Normal Sequencing of Esophagogastric Cancer. JAMA Network Open, 2021, 4, e2114753.	5.9	15
62	A phase I trial of intrahepatic Verapamil and doxorubicin. Regional therapy to overcome multidrug resistance. Cancer, 1994, 74, 2757-2764.	4.1	12
63	Phase II clinical trial of 13-cis-retinoic acid and interferon-?-2a in patients with advanced esophageal carcinoma. , 1999, 85, 1213-1217.		12
64	Use of positron emission tomography scan response to guide treatment change for locally advanced gastric cancer: the Memorial Sloan Kettering Cancer Center experience. Journal of Gastrointestinal Oncology, 2016, 7, 506-514.	1.4	12
65	Multimodality Therapy of Local Regional Esophageal Cancer. Seminars in Oncology, 2005, 32, 6-10.	2.2	11
66	Efficacy of Combined VEGFR1-3, PDGFÎ±/Î², and FGFR1-3 Blockade Using Nintedanib for Esophagogastric Cancer. Clinical Cancer Research, 2019, 25, 3811-3817.	7.0	10
67	A phase II trial of biochemical modulation using N- phosphonacetyl-L-aspartate, high-dose methotrexate, high-dose 5-fluorouracil, and leucovorin in patients with adenocarcinoma of unknown primary site. Cancer, 1992, 70, 1988-1992.	4.1	9
68	A phase I trial of a modified, dose intensive FAMTX regimen (High dose 5-fluorouracil + doxorubicin +) Tj ETQq0 0 0 rgBT /Overlock 10 Tf		9
69	Phase II trial of ifosfamide in epidermoid carcinoma of the esophagus: unexpectant severe toxicity. Investigational New Drugs, 1988, 6, 239-41.	2.6	8
70	Pilot study of rapid MR pancreas screening for patients with BRCA mutation. European Radiology, 2019, 29, 3976-3985.	4.5	8
71	A phase I trial of cisplatin in hypertonic saline and escalating doses of 5-fluorouracil by continuous intravenous infusion in patients with advanced malignancies. Cancer, 1990, 66, 1688-1691.	4.1	6
72	Prognostic significance of Tâ€cellâ€"inflamed gene expression profile and PDâ€L1 expression in patients with esophageal cancer. Cancer Medicine, 2021, 10, 8365-8376.	2.8	6

#	Article	IF	Citations
73	Conformation-Specific Inhibitory Anti-MMP-7 Monoclonal Antibody Sensitizes Pancreatic Ductal Adenocarcinoma Cells to Chemotherapeutic Cell Kill. Cancers, 2021, 13, 1679.	3.7	4
74	Acute toxicity of neoadjuvant bolus 5-FU/methotrexate and leucovorin rescue followed by continuous infusion 5-FU plus pre-operative radiation therapy for rectal cancer. Radiation Oncology Investigations, 1996, 4, 90-97.	0.9	3
75	Radical Resection of Rectal Cancer Primary Tumor Provides Effective Local Therapy in Patients With Stage IV Disease. Annals of Surgical Oncology, 2002, 9, 954-960.	1.5	3
76	Circulating tumor and invasive cell expression profiling predicts effective therapy in pancreatic cancer. Cancer, 2022, 128, 2958-2966.	4.1	2
77	Author reply. , 2000, 88, 2426-2426.		1
78	Reply to N. Fazio. Journal of Clinical Oncology, 2020, 38, 2467-2468.	1.6	1
79	Liver-directed conversion therapy in metastatic colon cancer. Journal of Gastrointestinal Oncology, 2015, 6, 322-8.	1.4	1
80	Phase I/Ib study of crenolanib with ramucirumab and paclitaxel as second-line therapy for advanced esophagogastric adenocarcinoma. Cancer Chemotherapy and Pharmacology, 2022, 89, 255-265.	2.3	1
81	Phase II study of CHIP chemotherapy in advanced adenocarcinomas of the upper gastrointestinal tract. Investigational New Drugs, 1990, 8, 71-5.	2.6	0
82	S-1 adjuvant chemotherapy for advanced gastric cancer. Nature Clinical Practice Oncology, 2008, 5, 370-371.	4.3	0